Cargando…
Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
AIM: The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian patients with type 2 diabetes mellitus (T2DM) who were prescribed either a sulfonylurea (SU) or a thiazolidinedione (TZD) in addition to the pr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600631/ https://www.ncbi.nlm.nih.gov/pubmed/18976457 http://dx.doi.org/10.1186/1477-7525-6-88 |
_version_ | 1782162187580604416 |
---|---|
author | Jermendy, György Erdesz, Diana Nagy, Laszlo Yin, Don Phatak, Hemant Karve, Sudeep Engel, Samuel Balkrishnan, Rajesh |
author_facet | Jermendy, György Erdesz, Diana Nagy, Laszlo Yin, Don Phatak, Hemant Karve, Sudeep Engel, Samuel Balkrishnan, Rajesh |
author_sort | Jermendy, György |
collection | PubMed |
description | AIM: The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian patients with type 2 diabetes mellitus (T2DM) who were prescribed either a sulfonylurea (SU) or a thiazolidinedione (TZD) in addition to the prior metformin (MF) monotherapy. METHODS: Type 2 diabetics aged ≥ 30 years and who had added an SU or TZD to previous MF monotherapy at least 1 year prior to the visit date were identified during January 2006 to March 2007. Information on HbA1c (A1C), medication use and co-morbid conditions was extracted from the medical record up to 6 months prior to the addition of SU or TZD to MF (baseline), and a minimum of one year after the initiation of either SU or TZD. Glycemic control (A1C < 6.5%) was assessed using the last available A1C value in the medical record. Self-reported hypoglycemia, health-related quality of life (HRQoL) and treatment satisfaction were also assessed. RESULTS: A total of 414 patients (82% SU+MF and 18% TZD+MF) with a mean age of 60.5 years (SD = 9.4 years) participated in the study. About 27% of patients reported hypoglycemic episodes, with about one-third reporting episodes that resulted into interruption of activities or required medical/non-medical assistance. Three quarters of patients were not at glycemic goal and BMI was the only factor significantly associated with failure to have an A1C level < 6.5%. Patients' HRQoL was significantly associated with self-reported hypoglycemic episodes (p = 0.017), and duration of diabetes (p = 0.045). CONCLUSION: Nearly 75% of patients were not at A1C goal of < 6.5% despite using two oral anti-hyperglycemic medications. Approximately 9% of patients reporting hypoglycemia required some kind of medical/non-medical assistance. Greater BMI at baseline was associated with an A1C level ≥ 6.5%. Finally, self- reports of hypoglycemia and duration of diabetes were associated with low HRQoL. |
format | Text |
id | pubmed-2600631 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-26006312008-12-12 Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary Jermendy, György Erdesz, Diana Nagy, Laszlo Yin, Don Phatak, Hemant Karve, Sudeep Engel, Samuel Balkrishnan, Rajesh Health Qual Life Outcomes Research AIM: The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian patients with type 2 diabetes mellitus (T2DM) who were prescribed either a sulfonylurea (SU) or a thiazolidinedione (TZD) in addition to the prior metformin (MF) monotherapy. METHODS: Type 2 diabetics aged ≥ 30 years and who had added an SU or TZD to previous MF monotherapy at least 1 year prior to the visit date were identified during January 2006 to March 2007. Information on HbA1c (A1C), medication use and co-morbid conditions was extracted from the medical record up to 6 months prior to the addition of SU or TZD to MF (baseline), and a minimum of one year after the initiation of either SU or TZD. Glycemic control (A1C < 6.5%) was assessed using the last available A1C value in the medical record. Self-reported hypoglycemia, health-related quality of life (HRQoL) and treatment satisfaction were also assessed. RESULTS: A total of 414 patients (82% SU+MF and 18% TZD+MF) with a mean age of 60.5 years (SD = 9.4 years) participated in the study. About 27% of patients reported hypoglycemic episodes, with about one-third reporting episodes that resulted into interruption of activities or required medical/non-medical assistance. Three quarters of patients were not at glycemic goal and BMI was the only factor significantly associated with failure to have an A1C level < 6.5%. Patients' HRQoL was significantly associated with self-reported hypoglycemic episodes (p = 0.017), and duration of diabetes (p = 0.045). CONCLUSION: Nearly 75% of patients were not at A1C goal of < 6.5% despite using two oral anti-hyperglycemic medications. Approximately 9% of patients reporting hypoglycemia required some kind of medical/non-medical assistance. Greater BMI at baseline was associated with an A1C level ≥ 6.5%. Finally, self- reports of hypoglycemia and duration of diabetes were associated with low HRQoL. BioMed Central 2008-10-31 /pmc/articles/PMC2600631/ /pubmed/18976457 http://dx.doi.org/10.1186/1477-7525-6-88 Text en Copyright © 2008 Jermendy et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Jermendy, György Erdesz, Diana Nagy, Laszlo Yin, Don Phatak, Hemant Karve, Sudeep Engel, Samuel Balkrishnan, Rajesh Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary |
title | Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary |
title_full | Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary |
title_fullStr | Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary |
title_full_unstemmed | Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary |
title_short | Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary |
title_sort | outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in hungary |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600631/ https://www.ncbi.nlm.nih.gov/pubmed/18976457 http://dx.doi.org/10.1186/1477-7525-6-88 |
work_keys_str_mv | AT jermendygyorgy outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT erdeszdiana outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT nagylaszlo outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT yindon outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT phatakhemant outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT karvesudeep outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT engelsamuel outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary AT balkrishnanrajesh outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary |